FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028343025> ?p ?o ?g. }

• W2028343025 endingPage "87" @default.
• W2028343025 startingPage "79" @default.
• W2028343025 abstract "The goal of this study was to evaluate, in patients with prostate cancer, the toxicity profile and biologic activity of the bispecific antibody MDXH210, which has specificity for the non–ligand-binding site of the high-affinity immunoglobulin G receptor (FcγRI) and the extracellular domain of the HER-2/neu proto-oncogene product. Patients with prostate cancer that expressed HER-2/neu were entered into a phase I dose-escalation trial of MDXH210. Patients received an intravenous infusion MDXH210 during a period of 2 h three times per week for 2 weeks and were monitored for toxicity. Pharmacokinetic and pharmacodynamic parameters were measured and included the biologic end points of monocyte-bound MDXH210, cytokine production, and clinical response. Seven patients were treated with MDXH210 doses ranging from 1 to 8 mg/m2. In general, MDXH210 was well tolerated, with only mild infusion-related malaise, fever, chills, and myalgias. No dose-limiting toxic effects were observed. Biologic effects included induction of low plasma concentrations of tumor necrosis factor-α and interleukin-6 observed immediately after MDXH210 infusion and 70% saturation of circulating monocyte-associated FcγRI with MDXH210 at a dose level of 4 to 8 mg/m2. Five of six patients had stable prostate-specific antigen levels during the course of 40 days or more. Circulating plasma HER-2/neu levels decreased by 80% at days 12 and 29 (p = 0.03 and 0.06, respectively, by the Wilcoxon signed rank test). MDXH210 can be given safely to patients with HER-2/neu–positive prostate cancer in doses of at least 8 mg/m2. At the doses studied, biologic activity was demonstrated and characterized by binding of MDXH210 to circulating monocytes, release of monocyte-derived cytokines, a decrease in circulating HER-2/neu, and short-term stabilization of prostate-specific antigen levels." @default.
• W2028343025 created "2016-06-24" @default.
• W2028343025 creator A5001550474 @default.
• W2028343025 creator A5013482829 @default.
• W2028343025 creator A5014192243 @default.
• W2028343025 creator A5031516173 @default.
• W2028343025 creator A5033544452 @default.
• W2028343025 creator A5061663602 @default.
• W2028343025 creator A5065404552 @default.
• W2028343025 creator A5068270443 @default.
• W2028343025 creator A5080500055 @default.
• W2028343025 creator A5083258118 @default.
• W2028343025 creator A5086364075 @default.
• W2028343025 creator A5089516753 @default.
• W2028343025 date "2001-01-01" @default.
• W2028343025 modified "2023-10-14" @default.
• W2028343025 title "Phase I Pilot Trial of the Bispecific Antibody MDXH210 (anti-FcγRI X anti–HER-2/neu) in Patients Whose Prostate Cancer Overexpresses HER-2/neu" @default.
• W2028343025 cites W1896751847 @default.
• W2028343025 cites W1971695978 @default.
• W2028343025 cites W1996455554 @default.
• W2028343025 cites W2041483436 @default.
• W2028343025 cites W2043752671 @default.
• W2028343025 cites W2084682642 @default.
• W2028343025 cites W2094273481 @default.
• W2028343025 cites W4238744887 @default.
• W2028343025 cites W45711525 @default.
• W2028343025 cites W51158438 @default.
• W2028343025 doi "https://doi.org/10.1097/00002371-200101000-00009" @default.
• W2028343025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11211151" @default.
• W2028343025 hasPublicationYear "2001" @default.
• W2028343025 type Work @default.
• W2028343025 sameAs 2028343025 @default.
• W2028343025 citedByCount "34" @default.
• W2028343025 countsByYear W20283430252014 @default.
• W2028343025 countsByYear W20283430252019 @default.
• W2028343025 countsByYear W20283430252020 @default.
• W2028343025 countsByYear W20283430252021 @default.
• W2028343025 crossrefType "journal-article" @default.
• W2028343025 hasAuthorship W2028343025A5001550474 @default.
• W2028343025 hasAuthorship W2028343025A5013482829 @default.
• W2028343025 hasAuthorship W2028343025A5014192243 @default.
• W2028343025 hasAuthorship W2028343025A5031516173 @default.
• W2028343025 hasAuthorship W2028343025A5033544452 @default.
• W2028343025 hasAuthorship W2028343025A5061663602 @default.
• W2028343025 hasAuthorship W2028343025A5065404552 @default.
• W2028343025 hasAuthorship W2028343025A5068270443 @default.
• W2028343025 hasAuthorship W2028343025A5080500055 @default.
• W2028343025 hasAuthorship W2028343025A5083258118 @default.
• W2028343025 hasAuthorship W2028343025A5086364075 @default.
• W2028343025 hasAuthorship W2028343025A5089516753 @default.
• W2028343025 hasBestOaLocation W20283430251 @default.
• W2028343025 hasConcept C111113717 @default.
• W2028343025 hasConcept C112705442 @default.
• W2028343025 hasConcept C121608353 @default.
• W2028343025 hasConcept C126322002 @default.
• W2028343025 hasConcept C203014093 @default.
• W2028343025 hasConcept C2776235491 @default.
• W2028343025 hasConcept C2776872082 @default.
• W2028343025 hasConcept C2778594517 @default.
• W2028343025 hasConcept C2780192828 @default.
• W2028343025 hasConcept C29730261 @default.
• W2028343025 hasConcept C530470458 @default.
• W2028343025 hasConcept C71924100 @default.
• W2028343025 hasConcept C90924648 @default.
• W2028343025 hasConcept C98274493 @default.
• W2028343025 hasConceptScore W2028343025C111113717 @default.
• W2028343025 hasConceptScore W2028343025C112705442 @default.
• W2028343025 hasConceptScore W2028343025C121608353 @default.
• W2028343025 hasConceptScore W2028343025C126322002 @default.
• W2028343025 hasConceptScore W2028343025C203014093 @default.
• W2028343025 hasConceptScore W2028343025C2776235491 @default.
• W2028343025 hasConceptScore W2028343025C2776872082 @default.
• W2028343025 hasConceptScore W2028343025C2778594517 @default.
• W2028343025 hasConceptScore W2028343025C2780192828 @default.
• W2028343025 hasConceptScore W2028343025C29730261 @default.
• W2028343025 hasConceptScore W2028343025C530470458 @default.
• W2028343025 hasConceptScore W2028343025C71924100 @default.
• W2028343025 hasConceptScore W2028343025C90924648 @default.
• W2028343025 hasConceptScore W2028343025C98274493 @default.
• W2028343025 hasIssue "1" @default.
• W2028343025 hasLocation W20283430251 @default.
• W2028343025 hasLocation W20283430252 @default.
• W2028343025 hasLocation W20283430253 @default.
• W2028343025 hasOpenAccess W2028343025 @default.
• W2028343025 hasPrimaryLocation W20283430251 @default.
• W2028343025 hasRelatedWork W1967489418 @default.
• W2028343025 hasRelatedWork W1984505191 @default.
• W2028343025 hasRelatedWork W2015453038 @default.
• W2028343025 hasRelatedWork W2018875428 @default.
• W2028343025 hasRelatedWork W2030254451 @default.
• W2028343025 hasRelatedWork W2254638634 @default.
• W2028343025 hasRelatedWork W2308319557 @default.
• W2028343025 hasRelatedWork W2369345461 @default.
• W2028343025 hasRelatedWork W2884757280 @default.
• W2028343025 hasRelatedWork W3030644989 @default.
• W2028343025 hasVolume "24" @default.
• W2028343025 isParatext "false" @default.
• W2028343025 isRetracted "false" @default.

• next